Next Article in Journal
The Multiple Mechanisms of Cell Death Triggered by Resveratrol in Lymphoma and Leukemia
Next Article in Special Issue
Importance of N-Glycosylation on CD147 for Its Biological Functions
Previous Article in Journal
Exogenous Asymmetric Dimethylarginine (ADMA) in Pathogenesis of Ischemia-Reperfusion-Induced Gastric Lesions: Interaction with Protective Nitric Oxide (NO) and Calcitonin Gene-Related Peptide (CGRP)
Previous Article in Special Issue
Towards Controlling the Glycoform: A Model Framework Linking Extracellular Metabolites to Antibody Glycosylation

P-Glycoprotein and Drug Resistance in Systemic Autoimmune Diseases

Department of Medical Sciences, Sapienza University of Rome, 2nd School of Medicine, Sant' Andrea University Hospital, 00189 Rome, Italy
Research Center Ospedale Pediatrico Bambino Gesù, IRCSS, Piazza S. Onofrio 4, 00165 Roma, Italy
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2014, 15(3), 4965-4976;
Received: 7 February 2014 / Revised: 6 March 2014 / Accepted: 13 March 2014 / Published: 20 March 2014
(This article belongs to the Special Issue Glycosylation and Glycoproteins)
Autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are chronic inflammatory disorders of unknown etiology characterized by a wide range of abnormalities of the immune system that may compromise the function of several organs, such as kidney, heart, joints, brain and skin. Corticosteroids (CCS), synthetic and biologic immunosuppressive agents have demonstrated the capacity to improve the course of autoimmune diseases. However, a significant number of patients do not respond or develop resistance to these therapies over time. P-glycoprotein (P-gp) is a transmembrane protein that pumps several drugs out of the cell, including CCS and immunosuppressants; thus, its over-expression or hyper-function has been proposed as a possible mechanism of drug resistance in patients with autoimmune disorders. Recently, different authors have demonstrated that P-gp inhibitors, such as cyclosporine A (CsA) and its analogue Tacrolimus, are able to reduce P-gp expression and or function in SLE, RA and PsA patients. These observations suggest that P-gp antagonists could be adopted to revert drug resistance and improve disease outcome. The complex inter-relationship among drug resistance, P-gp expression and autoimmunity still remains elusive. View Full-Text
Keywords: p-glycoprotein; autoimmune diseases; multidrug resistance; lymphocytes p-glycoprotein; autoimmune diseases; multidrug resistance; lymphocytes
MDPI and ACS Style

Picchianti-Diamanti, A.; Rosado, M.M.; Scarsella, M.; Laganà, B.; D'Amelio, R. P-Glycoprotein and Drug Resistance in Systemic Autoimmune Diseases. Int. J. Mol. Sci. 2014, 15, 4965-4976.

AMA Style

Picchianti-Diamanti A, Rosado MM, Scarsella M, Laganà B, D'Amelio R. P-Glycoprotein and Drug Resistance in Systemic Autoimmune Diseases. International Journal of Molecular Sciences. 2014; 15(3):4965-4976.

Chicago/Turabian Style

Picchianti-Diamanti, Andrea, Maria M. Rosado, Marco Scarsella, Bruno Laganà, and Raffaele D'Amelio. 2014. "P-Glycoprotein and Drug Resistance in Systemic Autoimmune Diseases" International Journal of Molecular Sciences 15, no. 3: 4965-4976.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop